KNIGHT THERAPEUTICS INC (GUD.CA) Fundamental Analysis & Valuation

TSX:GUD • CA4990531069

Current stock price

7.55 CAD
+0.05 (+0.67%)
Last:

This GUD.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. GUD.CA Profitability Analysis

1.1 Basic Checks

  • GUD had negative earnings in the past year.
  • In the past year GUD had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
  • Each year in the past 5 years GUD had a positive operating cash flow.
GUD.CA Yearly Net Income VS EBIT VS OCF VS FCFGUD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • GUD has a better Return On Assets (-0.51%) than 67.74% of its industry peers.
  • With a decent Return On Equity value of -0.70%, GUD is doing good in the industry, outperforming 70.97% of the companies in the same industry.
  • The Return On Invested Capital of GUD (0.38%) is better than 67.74% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for GUD is significantly below the industry average of 9.14%.
Industry RankSector Rank
ROA -0.51%
ROE -0.7%
ROIC 0.38%
ROA(3y)-0.61%
ROA(5y)-0.62%
ROE(3y)-0.8%
ROE(5y)-0.83%
ROIC(3y)0.73%
ROIC(5y)N/A
GUD.CA Yearly ROA, ROE, ROICGUD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4

1.3 Margins

  • Looking at the Operating Margin, with a value of 1.02%, GUD is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
  • With a decent Gross Margin value of 46.03%, GUD is doing good in the industry, outperforming 61.29% of the companies in the same industry.
  • GUD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 1.02%
PM (TTM) N/A
GM 46.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.63%
GM growth 5Y2.42%
GUD.CA Yearly Profit, Operating, Gross MarginsGUD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. GUD.CA Health Analysis

2.1 Basic Checks

  • GUD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • GUD has less shares outstanding than it did 1 year ago.
  • GUD has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, GUD has a worse debt to assets ratio.
GUD.CA Yearly Shares OutstandingGUD.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
GUD.CA Yearly Total Debt VS Total AssetsGUD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.49 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of GUD (2.49) is better than 87.10% of its industry peers.
  • The Debt to FCF ratio of GUD is 2.21, which is a good value as it means it would take GUD, 2.21 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of GUD (2.21) is better than 87.10% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that GUD is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.08, GUD is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 2.21
Altman-Z 2.49
ROIC/WACC0.04
WACC9.01%
GUD.CA Yearly LT Debt VS Equity VS FCFGUD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 2.39 indicates that GUD has no problem at all paying its short term obligations.
  • GUD has a Current ratio (2.39) which is in line with its industry peers.
  • GUD has a Quick Ratio of 1.57. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.
  • GUD has a better Quick ratio (1.57) than 70.97% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 1.57
GUD.CA Yearly Current Assets VS Current LiabilitesGUD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GUD.CA Growth Analysis

3.1 Past

  • The earnings per share for GUD have decreased strongly by -180.00% in the last year.
  • The Revenue has grown by 21.22% in the past year. This is a very strong growth!
  • GUD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.67% yearly.
EPS 1Y (TTM)-180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)21.22%
Revenue growth 3Y15.31%
Revenue growth 5Y17.67%
Sales Q2Q%37.42%

3.2 Future

  • Based on estimates for the next years, GUD will show a very strong growth in Earnings Per Share. The EPS will grow by 76.91% on average per year.
  • The Revenue is expected to grow by 6.88% on average over the next years.
EPS Next Y529.25%
EPS Next 2Y186.12%
EPS Next 3Y116.02%
EPS Next 5Y76.91%
Revenue Next Year13.69%
Revenue Next 2Y9.6%
Revenue Next 3Y7.56%
Revenue Next 5Y6.88%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GUD.CA Yearly Revenue VS EstimatesGUD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
GUD.CA Yearly EPS VS EstimatesGUD.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. GUD.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • GUD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 43.97 indicates a quite expensive valuation of GUD.
  • The rest of the industry has a similar Price/Forward Earnings ratio as GUD.
  • The average S&P500 Price/Forward Earnings ratio is at 21.36. GUD is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 43.97
GUD.CA Price Earnings VS Forward Price EarningsGUD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

  • 70.97% of the companies in the same industry are more expensive than GUD, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, GUD is valued a bit cheaper than 61.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.99
EV/EBITDA 10.81
GUD.CA Per share dataGUD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • GUD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • GUD's earnings are expected to grow with 116.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y186.12%
EPS Next 3Y116.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GUD.CA Dividend Analysis

5.1 Amount

  • GUD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GUD.CA Fundamentals: All Metrics, Ratios and Statistics

KNIGHT THERAPEUTICS INC

TSX:GUD (5/1/2026, 7:00:00 PM)

7.55

+0.05 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength30.71
Industry Growth47.76
Earnings (Last)03-19
Earnings (Next)05-07
Inst Owners19.51%
Inst Owner ChangeN/A
Ins Owners2.07%
Ins Owner ChangeN/A
Market Cap740.13M
Revenue(TTM)450.09M
Net Income(TTM)-5.37M
Analysts78
Price Target8.51 (12.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)298.02%
Min EPS beat(2)-692.08%
Max EPS beat(2)1288.12%
EPS beat(4)2
Avg EPS beat(4)36.72%
Min EPS beat(4)-815.07%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)-48.06%
EPS beat(12)6
Avg EPS beat(12)-79.01%
EPS beat(16)8
Avg EPS beat(16)-61.66%
Revenue beat(2)2
Avg Revenue beat(2)12.4%
Min Revenue beat(2)12.31%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)9.18%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)8
Avg Revenue beat(8)7.71%
Revenue beat(12)11
Avg Revenue beat(12)7.12%
Revenue beat(16)15
Avg Revenue beat(16)9.9%
PT rev (1m)5.13%
PT rev (3m)5.13%
EPS NQ rev (1m)-15.64%
EPS NQ rev (3m)N/A
EPS NY rev (1m)257.9%
EPS NY rev (3m)257.9%
Revenue NQ rev (1m)1.07%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)5.22%
Revenue NY rev (3m)5.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 43.97
P/S 1.64
P/FCF 20.99
P/OCF 10.73
P/B 0.96
P/tB 2.49
EV/EBITDA 10.81
EPS(TTM)-0.04
EYN/A
EPS(NY)0.17
Fwd EY2.27%
FCF(TTM)0.36
FCFY4.76%
OCF(TTM)0.7
OCFY9.32%
SpS4.59
BVpS7.83
TBVpS3.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.51%
ROE -0.7%
ROCE 0.52%
ROIC 0.38%
ROICexc 0.43%
ROICexgc 1.12%
OM 1.02%
PM (TTM) N/A
GM 46.03%
FCFM 7.83%
ROA(3y)-0.61%
ROA(5y)-0.62%
ROE(3y)-0.8%
ROE(5y)-0.83%
ROIC(3y)0.73%
ROIC(5y)N/A
ROICexc(3y)0.89%
ROICexc(5y)N/A
ROICexgc(3y)2.02%
ROICexgc(5y)N/A
ROCE(3y)1.02%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.63%
GM growth 5Y2.42%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 2.21
Debt/EBITDA 0.94
Cap/Depr 59.56%
Cap/Sales 7.49%
Interest Coverage 0.61
Cash Conversion 112.72%
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 1.57
Altman-Z 2.49
F-Score4
WACC9.01%
ROIC/WACC0.04
Cap/Depr(3y)46.19%
Cap/Depr(5y)129.54%
Cap/Sales(3y)6.33%
Cap/Sales(5y)23.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y529.25%
EPS Next 2Y186.12%
EPS Next 3Y116.02%
EPS Next 5Y76.91%
Revenue 1Y (TTM)21.22%
Revenue growth 3Y15.31%
Revenue growth 5Y17.67%
Sales Q2Q%37.42%
Revenue Next Year13.69%
Revenue Next 2Y9.6%
Revenue Next 3Y7.56%
Revenue Next 5Y6.88%
EBIT growth 1Y352.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year431.15%
EBIT Next 3Y81.28%
EBIT Next 5Y50.35%
FCF growth 1Y633.42%
FCF growth 3Y22.5%
FCF growth 5YN/A
OCF growth 1Y90.07%
OCF growth 3Y15.29%
OCF growth 5YN/A

KNIGHT THERAPEUTICS INC / GUD.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 5 / 10 to GUD.CA.


What is the valuation status for GUD stock?

ChartMill assigns a valuation rating of 4 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Fairly Valued.


How profitable is KNIGHT THERAPEUTICS INC (GUD.CA) stock?

KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for GUD stock?

The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to grow by 529.25% in the next year.